title: Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.
abstract: An open-label study was performed to investigate the clinical efficacy and tolerability of olanzapine orally disintegrating tablets (Zyprexa Zydis) in ameliorating excitement symptoms in the acute phase of schizophrenia. Fifty-three patients meeting DSM-IV criteria for first-episode schizophrenia and treated with olanzapine monotherapy were evaluated with regard to their clinical improvement, behavioural response to medication, and extrapyramidal side effects using the Positive and Negative Syndrome Scale Excited Component (PANSS-EC), Nursing Assessment of Medication Acceptance (NAMA), and Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), respectively. Scores of PANSS-EC were significantly reduced after 3 days of olanzapine administration. A reduction in NAMA scores was also observed 7 days after administration of olanzapine. The DIEPSS score was unaffected by olanzapine administration. These results suggest that olanzapine orally disintegrating tablets are effective and well-tolerated for treatment excitement in the acute phase of schizophrenic patients. In addition, it is possible that adherence to medications is improved by using olanzapine orally disintegrating tablets.
authors.affiliation: Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Iseigaoka, Yahatanishiku, Kitakyusyu, Fukuoka, Japan.
authors.forename: Hikaru
authors.initials: H
authors.lastname: Hori
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Ueda
authors.forename: Reiji
authors.initials: R
authors.lastname: Yoshimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Kenta
authors.initials: K
authors.lastname: Wani
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Etoh
authors.forename: Kensuke
authors.initials: K
authors.lastname: Haraga
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitahara
authors.forename: Jun
authors.initials: J
authors.lastname: Nakamura
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000453:epidemiology; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009055:Mouth; D000077152:Olanzapine; D010349:Patient Compliance / Q000706:statistics & numerical data; D011446:Prospective Studies; D011595:Psychomotor Agitation / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index; D012995:Solubility; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine